Impact of unresolved neutropenia in patients with neutropenia and invasive aspergillosis: a post hoc analysis of the SECURE trial | Zendy

Dimitrios P. Kontoyiannis | Zendy; Dominik Selleslag | Zendy; Kathleen M. Mullane | Zendy; Oliver A. Cornely | Zendy; William Hope | Zendy; Olivier Lortholary | Zendy; Rodney CroosDabrera | Zendy; Christopher Lademacher | Zendy; Marc Engelhardt | Zendy; Thomas F. Patterson | Zendy

Open Access

Impact of unresolved neutropenia in patients with neutropenia and invasive aspergillosis: a post hoc analysis of the SECURE trial

Author(s) -

Dimitrios P. Kontoyiannis,

Dominik Selleslag,

Kathleen M. Mullane,

Oliver A. Cornely,

William Hope,

Olivier Lortholary,

Rodney CroosDabrera,

Christopher Lademacher,

Marc Engelhardt,

Thomas F. Patterson

Publication year - 2017

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dkx423

Subject(s) - neutropenia , aspergillosis , medicine , post hoc analysis , post hoc , intensive care medicine , immunology , chemotherapy

Historically, baseline neutropenia and lack of neutrophil recovery have been associated with poor outcomes in invasive aspergillosis (IA). It is unclear how treatment with the new Aspergillus-active triazoles isavuconazole and voriconazole affects outcomes in neutropenic patients with IA.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research